

Innovus Pharma


CORPORATE PROFILE

Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application ("ANDA") products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

9171 Towne Centre Drive, Ste 440 IR@InnovusPharma.com
San Diego, CA 92122 T: (858) 964-5123
Phone: (858) 964-5123
Fax: (858) 249-7879
<http://www.innovuspharma.com>
info@innovuspharma.com

STOCK PERFORMANCE

Symbol	INNV
Exchange	OTCQB
Market Cap.	16.92m
52 Week Range	0.082 - 0.663
Close	0.117
Volume	663
Shares Outstanding	150,535,774
As of Jul 25, 2017 3:59 pm	



MANAGEMENT TEAM

Bassam Damaj, Ph.D. - President and Chief Executive Officer

Randy Berholtz, MBA/JD - Executive Vice President, Corporate Development and General Counsel

Rauly Gutierrez, CPA - Vice President, Finance and Principal Financial and Accounting Officer

RECENT HEADLINES

[Jul 24, 2017 - Innovus Pharma Announces Combined Launch of Apezaz\(TM\) Cream for Arthritis Pain Relief, and ArthriVarx\(TM\), a Supplement Designed to Maximize and Support Joint Health](#)

[Jul 20, 2017 - Innovus Pharma's Partner Luminarie Receives Approval for Zestra® for Female Sexual Arousal Disorder as a Medical Device I from Australia's Therapeutic Goods Administration](#)

[Jun 13, 2017 - Innovus Joins Eli Lilly and Novartis in the Race to Develop Products for Oncology \(Cachexia\) -- SECFilings.com](#)

[Jun 6, 2017 - Innovus Pharma to Enter the Oncology Supportive Care Market With an Exclusive License to Two GRAS-Listed OTC Compounds for Cachexia and Muscle Growth and Repair From the University of Iowa Research Foundation](#)

[Jun 1, 2017 - NetworkNewsBreaks - SeeThruEquity Updates Coverage with \\$0.65 PT on Innovus Pharmaceuticals, Inc. \(OTCQB: INNV\)](#)

PAST EVENTS

Apr 30, 2016 - The San Diego Union Tribune Successful Aging Expo